This year, CRAN celebrates its 40th anniversary.

1980-2020: 40 years of history for CRAN.


This year, CRAN celebrates its 40th anniversary. This event will be celebrated on Thursday 15 and Friday 16 October 2020!

40 years of commitment to advancing research in Automation and opening up to new disciplines such as signal and image processing, biology and medicine. During its 4 decades, the laboratory has been enriched by collaborations and equipped with state-of-the-art equipment.

On this occasion, CRAN is organising a meeting that will feature 4 guest speakers on topics related to the laboratory, testimonials from CRAN members and contributions from our tutelles, the University of Lorraine and the CNRS.

This celebration will honour the scientific and human values that have characterised CRAN since its creation. It is useful to be aware of the path we have travelled and the major changes that have taken place. By retracing 40 years of history, we will evoke its multiple collaborations, its highlights and present the perspectives offered by the future.

These 2 days will bring together the members of the laboratory, former members, partners, and academic personalities linked to the laboratory.


Thursday 15 October / 8.30 pm

Faculty of Science and Technology - amphitheatre 8

Open to the general public | Free admission

"Reducing Parkinson's brain oscillations thanks to the automatic system".

Speaker / Antoine Chaillet, Professor at Centrale Supélec, Paris

As part of the Science and Society conference series

Summary : The symptoms of Parkinson's disease are correlated with cerebral oscillations in certain deep areas of the brain. Deep brain stimulation, in which these areas are stimulated with weak electrical impulses using implanted electrodes, counteracts these oscillations and thus considerably improves the patients' quality of life. However, the stimulation strategies currently used in the clinic operate in an open loop, i.e. the stimulation signal is always the same, regardless of the patient's condition or activity. Furthermore, the mechanisms by which these pathological oscillations occur are still unknown. In this talk, I will show how the tools of Automation can be used to respond to these challenges. I will present in a didactic way how the activity of the brain structures involved can be mathematically modelled and will present two main hypotheses concerning the mechanisms of generation of pathological oscillations. I will propose stimulation strategies capable of adapting in real time to the brain activity of the patient and of attenuating the cerebral oscillations in these two generation hypotheses. I will demonstrate the efficiency of these strategies both mathematically and on the basis of detailed numerical models of the brain networks concerned. Finally, I will discuss other neuroscience problems in which Automatic Control could prove useful.

Friday 16 October / 14h

Proven Convention Centre of Nancy

By invitation

14h | Opening by Didier Wolf, Director of CRAN

14h15 | " Theranostic hybrid particles for a breakthrough nanomedicine: from the bench to the first clinical trials "
Speaker / Olivier Tillement, Professor at the University Claude Bernard Lyon1 , Institut Lumière Matière (ILM-UMR 5306)

Summary: This conference will focus on the emerging field of nanomedicine. In particular, a new class of hybrid theranostic nanoparticles will be presented. These nanoparticles combine a diagnostic function by acting as a contrast agent for Magnetic Resonance Imaging (MRI), and a therapeutic function by accentuating locally, i.e. within the tumour, the dose of toxic radiation under irradiation.
After about ten years of laboratory research and preclinical development, these objects of less than 5 nm, consisting of a polysiloxane© core surrounded by gadolinium chelates, are now produced under cGMP conditions. These hybrid nano-objects are the basis of the AGuIX© nano-drug, which is now being evaluated in clinical studies.
The design of these nanoparticles allows them to be administered by simple intravenous injection. Furthermore, their effectiveness is based on their nanometric structure, which allows the combination of three clinical advantages essential for combating tumours: targeting, imaging and treatment.
By accumulating nanoparticles specifically at the heart of tumours, a new way of treating patients is proposed that combines more precise MRI-guided radiotherapy with radiation-sensitising nanomedicine. The aim of the drugs based on the AGuIX© theranostic nanoplateform is to significantly improve the treatment of tumours.